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What is the safest way to use thalidomide therapy for dermatolo-
gic diseases? Speci¢cally, what is the risk of peripheral neuropathy
associated with thalidomide therapy? These are critical questions
for physicians and patients alike that have yet to be satisfactorily
answered. Major concerns related to the use of thalidomide are its
teratogenic properties and peripheral neuropathy. By following
the guidelines of the STEPS (System for Thalidomide Education
and Prescribing Safety) program, the former problem can be ad-
dressed by careful patient selection, interventions to prevent preg-
nancy, counseling and close patient monitoring for compliance
with a de¢ned contraception program. However, there is no ef-
fective method to prevent peripheral neuropathy. Early recogni-
tion of this side-e¡ect is imperative, as the prognosis for recovery
from symptomatic neuropathy may be optimal with early with-
drawal of this drug (Fullerton and O’Sullivan, 1968).
Estimates of the prevalence of thalidomide neuropathy in der-
matology patients range from 1 to 70%, and have been limited by
a paucity of studies that directly studied this issue (Knop et al,
1983; Ochonisky et al, 1994; Herranz et al, 1998; Lagueny et al,
1986; Tseng et al, 1996). Some of these studies have been limited
by small, heterogeneous patient samples, retrospective nature of
the studies, di¡erent dosing regimens, the sources of thalidomide
drug, heterogeneity in the frequency and nature of the neurophy-
siologic testing, and short duration of follow-up, as well as the
de¢nition of what constitutes a thalidomide neuropathy. Thus,
the quality of the evidence related to this important issue has
not been uniform and therefore has been suboptimal.
In the study by Bastuji-Garin et al many of the limitations of
the previous studies are appropriately addressed. The strengths of
this work are its prospective nature, relatively large patient size
(135 patients), sustained period of observation (up to 2 years),
careful study design, and uniform clinical and neurophysiologic
criteria for neuropathy across 32 di¡erent dermatology depart-
ments in France. As a result of these considerable e¡orts, there
are a number of answers to important questions of concern to
physicians and patients alike related to thalidomide neurotoxicity.
Some of these answers are disconcerting, some results re-a⁄rm
those of previous studies, some points are surprising, and some
results raise even further questions.
The disconcerting data are related to what the authors describe as
‘safe’doses of thalidomide (25 mg daily dosing), where the risk of
neurotoxicity seems negligible. This low daily dose may be safe,
but considering that this agent is typically utilized to treat severe,
treatment-resistant diseases that have failed ¢rst and second line
agents (for example, chronic cutaneous lupus erythematosus),
these very low, ‘safe’doses as an initial monotherapy are not prac-
tical. In the typical scenario, higher doses (typically 100 mg per
day, but potentially as high as 200^400 mg per day) are utilized
to induce a clinical anti-in£ammatory response over approxi-
mately 16 weeks. The drug is then weaned over time to
lower doses such as 25 mg daily or even two-three times per
week dosing intervals. Thus, at these typical starting doses of
thalidomide, there is a dose-related risk of neuropathy that may
occur rapidly. While this information is cause for concern, now
there is more precise information that will be useful for risk
assessment.
This study re-a⁄rms an overall 25% prevalence of clear-cut
thalidomide neuropathy, which had been suggested by two prior
studies of dermatology patients treated with thalidomide (Knop
et al, 1983; Ochonisky et al, 1994).While 25% of their population
developed an obvious drug-induced peripheral neuropathy, if all
of their potential cases were considered, this rate was as high as
56%.These ‘atypical neuropathies’, which constituted a signi¢cant
proportion of this study population (another 31% beyond the
‘de¢nite neuropathies’), indicate the challenges of con¢rming the
diagnosis of thalidomide neuropathy, and raise questions about
what clinical and neurophysiologic criteria should be used to
de¢ne what constitutes a thalidomide neuropathy.This study also
con¢rms the importance of the reliability of symptoms reported
by patients, as the ¢rst clinical abnormalities were subjective in
81% of the patients with thalidomide neuropathy.
Previous studies had suggested that there may be a variety of
host-related risk factors for developing a thalidomide peripheral
neuropathy, which include the patient’s age, cumulative doses of
thalidomide, and underlying disease state. None of these factors
were identi¢ed in the present study. Another host-related factor
that has not been adequately addressed in past studies is that of
drug metabolism and its relationship to peripheral neuropathy.
One uncon¢rmed, small study suggested that thalidomide neu-
rotoxicity can cluster in families, suggesting that slow acetylators
may be at risk for this condition (Hess et al, 1986). The Thalido-
mide Neuropathy Study Group is in a position to address the
pharmacogenetics of thalidomide neurotoxicity. Comparative
studies of their ‘No neuropathy’ group to that of the ‘De¢nite
neuropathy’ group may provide further evidence for the validity
of this hypothesis.
Another important point not addressed in this study is the nat-
ural history of thalidomide neurotoxicity after its onset. Previous
natural history studies of patients followed for 4^6 years (follow-
ing cessation of thalidomide) have shown that neuropathic symp-
toms and signs remain unchanged in 50%, improve in 25%, and
resolve in 25%. Improvement can be delayed for years (Lagueny
et al, 1986). However, abnormalities on nerve conduction studies
only rarely improve, despite clinical improvement (Fullerton and
O’Sullivan, 1968, Lagueny et al, 1986).
Bastuji-Garin et al monitored the patients in their cohort clo-
sely for the development of the signs and symptoms of thalido-
mide-induced neuropathy. Thus, this agent was discontinued
early in the course of the neuropathy, which may be associated
with a better outcome for symptomatic reversal of this toxic re-
action. The Thalidomide Neuropathy Study Group is well-posi-
tioned to address this issue over time. Information related to the
natural history of the neurologic changes derived from the ‘De¢-
nite neuropathy’ and ‘Atypical neuropathy’ patient groups will
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advance the level of knowledge in important aspects of thalido-
mide neurotoxicity.
The Thalidomide Neurotoxicity Study Group did not state its
source of thalidomide used to treat the cohort of patients with
skin disease, but it is likely that they obtained this drug from
Laboratoires Laphal. In the United States alone, there are four
pharmaceutical companies that manufacture and distribute this
drug. Worldwide, there are a number of commercial entities,
state-sponsored facilities and ‘Black Market’ sources that manufac-
ture and distribute this drug. The e¡ect of the source of thalido-
mide used to treat patients with dermatologic diseases has not
been addressed. Bio-equivalence studies of thalidomide from dif-
ferent manufacturers will be of critical importance to identify the
safest, most e¡ective preparations of this drug, or at least con¢rm
that heterogeneity of thalidomide from di¡erent sources is not an
issue.
Their data con¢rm the need for more research related to the
clinical uses of this pharmacologic agent. Of particular interest
will be the newer thalidomide derivatives. These newer deriva-
tives can be divided into two distinct classes: the class I agents,
the Immunomodulatory Imide Drugs (ImiDs) and the class II
agents, the Selective cytokine inhibitory drugs (Selcids) (Corral
et al, 1999). Some of these derivatives may exhibit little or no neu-
rotoxic potential.While these newer thalidomide derivatives are
in development, the data provided by the Thalidomide Neuro-
toxicity Study Group are an important step forward in risk as-
sessment for using this agent to treat selected patients with
refractory skin diseases.
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